Hemab Therapeutics Hldgs Q1 EPS $(23.98) Down From $(16.18) YoY

Benzinga Newsdesk www.benzinga.com Negative 97.2%

Neg 97.2% Neu 0% Pos 0%

Hemab Therapeutics Hldgs (NASDAQ:COAG) reported quarterly losses of $(23.98) per share. This is a 48.21 percent decrease over losses of $(16.18) per share from the same period last year.